PharVision Advisers’s Concentrix CNXC Stock Holding History

PharVision Advisers’s Portfolio CNXC Stock Details CNXC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,752	Closed	-$465K	–	313
2024 Q4	$465K	Buy	+10,752	New	+$478K	0.39%	53

Other funds holding CNXC

GBL

Groupe Bruxelles Lambert Brussels, Belgium $62.2M AUM 57.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $199B AUM 37.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PharVision Advisers's CNXC Position: Q1 2025 in Review

PharVision Advisers sold out of Concentrix (CNXC) in Q1 2025, closing a stake of 10,752 shares — an estimated $465K sold.

PharVision Advisers first reported a position in CNXC in Q4 2024 and held it in 1 quarter. The position peaked at $465K in Q4 2024. 346 funds tracked by Wall St. Rank hold CNXC as of Q1 2025.

PharVision Advisers reported no remaining Concentrix position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 10,752 Concentrix shares in Q1 2025, an estimated $465K.
PharVision Advisers first reported a position in Concentrix in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Concentrix position peaked at $465K in Q4 2024.
346 funds tracked by Wall St. Rank held Concentrix as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.